QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lantz, R. J. Articles by Knadler, M. P. Search for Related Content PubMed PubMed Citation Articles by Lantz, R. J. Articles by Knadler, M. P.

METABOLISM, EXCRETION, AND PHARMACOKINETICS OF DULOXETINE IN HEALTHY HUMAN SUBJECTS

Departments of Drug Disposition (R.J.L., T.A.G., T.J.R., F.K., M.P.K.) and Pharmacokinetics (H-Y.K.), Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana; and Clinical Pharmacology, Eli Lilly and Company, and Indiana University School of Medicine, Indianapolis, Indiana (M.S.)

Duloxetine is a potent and balanced dual inhibitor of serotonin and norepinephrine reuptake being investigated for the treatment of depression and urinary incontinence. The disposition of duloxetine was studied in four healthy human subjects after a single 20.2-mg (100.6 µCi) oral dose of [¹⁴C]duloxetine in an enteric-coated tablet. The mean total recovery of radioactivity (± S.E.M.) after 312 h was 90.5% (±0.4%) with 72.0% (±1.1%) excreted in the urine. Duloxetine was extensively metabolized to numerous metabolites primarily excreted into the urine in the conjugated form. The major biotransformation pathways for duloxetine involved oxidation of the naphthyl ring at either the 4-, 5-, or 6-positions followed by further oxidation, methylation, and/or conjugation. The major metabolites found in plasma were glucuronide conjugates of the following: 4-hydroxy duloxetine (M6), 6-hydroxy-5-methoxy duloxetine (M10), 4, 6-dihydroxy duloxetine (M9), and a sulfate conjugate of 5-hydroxy-6-methoxy duloxetine (M7). The major metabolites found in plasma were also found in the urine, but the urine contained many additional metabolites. In addition to duloxetine, 4-hydroxy duloxetine (M14) and an unidentified polar metabolite were observed in feces. Following [¹⁴C]duloxetine administration, C_max was reached at a median of 6 h for both duloxetine and total radioactivity. Duloxetine accounted for less than 3% of the circulating radioactivity based on mean area under the curve values. The elimination half-life of total radioactivity (120 h) was substantially longer than that of duloxetine (10.3 h).

This article has been cited by other articles:

				S. Englisch, U. Knopf, B. Scharnholz, A. Kuwilsky, M. Deuschle, and M. Zink Duloxetine for major depressive episodes in the course of psychotic disorders: an observational clinical trial J Psychopharmacol, November 1, 2009; 23(8): 875 - 882. [Abstract] [PDF]

				B. L. Paris, B. W. Ogilvie, J. A. Scheinkoenig, F. Ndikum-Moffor, R. Gibson, and A. Parkinson In Vitro Inhibition and Induction of Human Liver Cytochrome P450 Enzymes by Milnacipran Drug Metab. Dispos., October 1, 2009; 37(10): 2045 - 2054. [Abstract] [Full Text] [PDF]

				S. Ohmori, M. Miura, C. Toriumi, Y. Satoh, and T. Ooie Absorption, Metabolism, and Excretion of [14C]Imidafenacin, a New Compound for Treatment of Overactive Bladder, After Oral Administration to Healthy Male Subjects Drug Metab. Dispos., September 1, 2007; 35(9): 1624 - 1633. [Abstract] [Full Text] [PDF]

				A. D. Westanmo, J. Gayken, and R. Haight Duloxetine: A balanced and selective norepinephrine- and serotonin-reuptake inhibitor Am. J. Health Syst. Pharm., December 1, 2005; 62(23): 2481 - 2490. [Abstract] [Full Text] [PDF]

				S. E Dugan and M. A Fuller Duloxetine: A Dual Reuptake Inhibitor Ann. Pharmacother., December 1, 2004; 38(12): 2078 - 2085. [Abstract] [Full Text] [PDF]